Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MK-4280A |
| Trade Name | |
| Synonyms | MK4280A|MK 4280A |
| Drug Descriptions |
MK-4280A is a coformulation of MK-4280 and Pembrolizumab, which potentially induces antitumor activity (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3584). |
| DrugClasses | Immune Checkpoint Inhibitor 150 LAG3 Antibody 19 PD-L1/PD-1 antibody 132 |
| CAS Registry Number | NA |
| NCIT ID | C190780 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Enfortumab vedotin-ejfv + MK-4280A | Enfortumab vedotin-ejfv MK-4280A | 0 | 1 |
| Irinotecan + MK-4280A | Irinotecan MK-4280A | 0 | 1 |
| Lenvatinib + MK-4280A | Lenvatinib MK-4280A | 0 | 2 |
| MK-4280A | MK-4280A | 0 | 7 |
| MK-4280A + Paclitaxel | MK-4280A Paclitaxel | 0 | 1 |